Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 37126762

Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
J Clin Oncol
Publication date
2023 Jul 1
First author
Harrison CN

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Harrison CN
      type
      Author
    2. name
      Nangalia J
      type
      Author
    3. name
      Boucher R
      type
      Author
    4. name
      Jackson A
      type
      Author
    5. name
      Yap C
      type
      Author
    6. name
      O'Sullivan J
      type
      Author
    7. name
      Fox S
      type
      Author
    8. name
      Ailts I
      type
      Author
    9. name
      Dueck AC
      type
      Author
    10. name
      Geyer HL
      type
      Author
    11. name
      Mesa RA
      type
      Author
    12. name
      Dunn WG
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Harrison CN
      type
      Author
    2. name
      Nangalia J
      type
      Author
    3. name
      Boucher R
      type
      Author
    4. name
      Jackson A
      type
      Author
    5. name
      Yap C
      type
      Author
    6. name
      O'Sullivan J
      type
      Author
    7. name
      Fox S
      type
      Author
    8. name
      Ailts I
      type
      Author
    9. name
      Dueck AC
      type
      Author
    10. name
      Geyer HL
      type
      Author
    11. name
      Mesa RA
      type
      Author
    12. name
      Dunn WG
      type
      Author
    bibliography ids
    1. nci-bib-81db82d1cb32a16f74ee8f57
    book metadata
    content sha256
    5de314ad72864970e018eb239ed8127fbb392215e78451967d6356c512501ce7
    document type
    citation
    dois
    1. 10.1200/JCO.22.01935
    electronic publication date
    display
    2023 May 1
    precision
    day
    year
    2023
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:37126762
    immutable id
    pubmed:37126762@5de314ad72864970e018eb239ed8127fbb392215e78451967d6356c512501ce7
    journal
    abbreviation
    J Clin Oncol
    issn electronic
    1527-7755
    issn print
    0732-183X
    issue
    19
    name
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    nlm unique id
    8309333
    pages
    3534-3544
    volume
    41
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      37126762
      provenance
      batch id
      5329a5d0877ee70ecd11
      provider
      NCBI PubMed ESummary
      record sha256
      a336e5f7e2983346a0b9a59d428cfbeb6eda3148719225c1fcf9f99c8f42168a
      response sha256
      bcc4d4935bae07b2d0bf7ef24187cf1ff9d849601f315c9dbe2002bd5de6f631
      retrieved at
      2026-09-09T23:48:15.763286+00:00
      publication date
      display
      2023 Jul 1
      precision
      day
      year
      2023
      publication types
      1. Randomized Controlled Trial
      2. Clinical Trial, Phase II
      3. Journal Article
      4. Research Support, Non-U.S. Gov't
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/37126762/
      title
      Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial.

      Preserved source evidence · Not medical advice